How EMPAVELI can help | HEMOGLOBIN
Stabilized hemoglobin with EMPAVELI
Stabilized hemoglobin (Hb) levels in people who had never received a complement inhibitor: results at Week 26* One of the primary goals in the PRINCE study: to explore whether EMPAVELI stabilized hemoglobin in people living with PNH not previously treated with a complement inhibitor
In people who had never received a complement inhibitor (PRINCE)
Stacey is an adult with PNH who's taken EMPAVELI.
90
75
86% ( P <0.0001)
60
of people taking EMPAVELI achieved Hb stabilization over 26 weeks
45
30
15
0%
0
IMPORTANT SAFETY INFORMATION (cont’d) Before you take EMPAVELI, tell your healthcare provider about all of your medical
EMPAVELI n=35
Control arm (excluding complement inhibitors) n=18
conditions, including if you: have an infection or fever.
are pregnant or plan to become pregnant. EMPAVELI may harm your unborn baby. Females who are able to become pregnant should have a pregnancy test before starting treatment with EMPAVELI and use an effective method of birth control during treatment with EMPAVELI and for 40 days after the last dose. are breastfeeding or plan to breastfeed. It is not known if EMPAVELI passes into your breast milk. You should not breastfeed during treatment with EMPAVELI and for 40 days after the last dose.
*Hb stabilization means avoiding a >1 g/dL decrease in Hb levels throughout the study.
PNH=paroxysmal nocturnal hemoglobinuria.
Please see full Important Safety Information, including Boxed WARNING regarding risk of serious infections, on pages 38-39, and the full Prescribing Information and Medication Guide.
12
13
Made with FlippingBook - professional solution for displaying marketing and sales documents online